Sheffield, UK, April 2025: SynGenSys, a biotechnology company designing synthetic gene promoter systems to address critical bottlenecks in biopharma manufacturing and enhance cell and gene therapy development, today announced the extension of its seed funding with an additional £1.4M, led by SynGenSys’ angel group to advance its synthetic promoter systems, bringing the total raised in the round to £3.2M.
The funding will support the Company’s transition from R&D to commercialisation, extending the team’s scientific capacity to test its proprietary promoter systems in representative in vivo models, and to begin working on the next generation of promoters and signal peptides for biomanufacturing operations.
SynGenSys had previously received pre-seed and seed funding from the University of Sheffield, UKRI, Takeda, and a consortium of angel investors. Led by Charles Gillespie, the angel investors are based in the South Yorkshire region, with backgrounds in financial services, banking, science, technology, and manufacturing.
